Giant Axonal Neuropathy (GAN)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Giant Axonal Neuropathy (GAN) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT07543991

Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)

Giant axonal neuropathy (GAN) is a rare pediatric disorder caused by autosomal recessive mutations in the GAN gene. GAN is a multisystem, neurodegenerative diso…

United States4 participantsStarted 2026-03-01

Treatment: scAAV9/JeT-GAN

All recent trials (3 shown)

CompletedPhase 1

NCT02362438

Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy

Title: Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy Background: \- The Gigaxonin gene lets the body make a protei…

United States14 participantsStarted 2015-04-24

Treatment: scAAv9/JeT-GAN

TerminatedNot Applicable

NCT01503125

Giant Axonal Neuropathy Natural History Study

Giant Axonal Neuropathy (GAN) is a devastating and rare childhood disease. Children with GAN develop increasing muscle weakness, impaired sensation, and at time…

United States13 participantsStarted 2011-12